Pfizer Inc. (PFE) and BioNTech's (BNTX) COVID-19 vaccine BNT162b2 has demonstrated 100% efficacy and robust antibody responses in a phase III trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the companies said in a statement.
The trial enrolled 2,260 adolescents 12 to 15 years of age in the United States.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com